by Andrea Corona – Drug Discovery and Development –
The field’s foundational biology is no longer the limiting factor. What comes next depends on whether the industry can build the manufacturing, commercial, and clinical infrastructure to match what the science already knows how to do.
Cell and gene therapy (CGT) has arrived. The question a panel at the Convention on Pharmaceutical Ingredients (CPHI) Americas 2026 in Philadelphia spent an hour working through was not whether these modalities work — it was whether the industry surrounding them is built for what comes next.
